ALK and non-small cell lung carcinoma: Besides EGFR, the discovery of ALK as a druggable oncogenic pathway in NSCLC led to the identification of an additional oncogene-addicted subgroup of NSCLC, for which the administration of ALK inhibitors completely changed the natural course of the disease.